ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / RVP / forecast
MODD (33) PAVM (28) CTSO (22) PMI (48) ⌘ Pro Terminal →

Retractable Technologies Inc. (RVP) 12-Month Stock Forecast & Price Target Cone

$0.56 -1.96% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.56

Retractable Technologies Inc. (RVP) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $16.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RVP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RVP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Retractable Technologies Inc. (NYSE: RVP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.56 (-1.96% 1D, market cap $16.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RVP ranks #772 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RVP compare to MODD and PAVM in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), RVP carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 0.1%, and ROIC of -23.3%. By comparison, MODD (Modular Medical Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and PAVM (PAVmed Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $15.6M). Among the 5-stock peer group, RVP leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RVP?
▼

Per RVP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000946563), Retractable Technologies Inc. generated $38.3M in revenue (+15.8% YoY), -$12.6M in net income, and -$7.1M in free cash flow against $142.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.56 (-0.54%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (5)Whales (11)SEC (5)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.5% Base Target
$1 Bull$0 Base$0 Bear
📬 FREE RVP RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RVP)Realized 20D OHLCV Swing Band: ±5.3%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY RVP SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (35% of score)

20D Institutional Volume Accumulation (±5.3% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (23% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 25 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$0.61-4.9% Next Q
Q2 (-2Q)
36
Grade E$0.58+1.7% Next Q
Q3 (-1Q)
34
Grade E$0.59-5.1% Next Q
Current
31
Grade E$0.56-9.4% Hist 90D α
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RVP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RVP currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.66) and Max Pain ($0.59) forces dealer call-delta covering toward $0.95.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RVP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RVP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your RVP Position Size: $10,000

Shares at $0.56: 17857.1 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $0.38
$6,786
$-3,214 (-32.1%)
12M Consensus BaseTarget $0.49
$8,750
$-1,250 (-12.5%)
12M Bull Case BreakoutTarget $0.95
$16,964
+$6,964 (+69.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$169%B
JP MorganUS Large-Cap ResearchSELL$058%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RVP)

  • ✓Walkthrough of RVP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RVP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.85%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.57H $0.57L $0.56C $0.56VOL 33.3K
RES: $0.73SUP: $0.56SMA50: $0.66SMA200: $0.68
$0.78$0.72$0.66$0.60$0.54RES $0.73SUP $0.56$0.562026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RVP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RVP Butterfly Map → + Track RVP →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +15.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RVP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RVP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RVP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RVP)

Health Care Rank #772 of 1015 ⚔️ MODD vs RVP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RVP vs. MODD, PAVM, CTSO, PMI)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Retractable Technologies Inc. (RVP) ranks #772 by composite RQD confidence (31/100, grade E) and #839 by equity capitalization ($16.9M). Within this direct 5-issuer industry benchmark cohort, RVP leads on earnings valuation at N/A trailing P/E, while RVP leads on capital efficiency and profitability with -23.3% ROIC and 0.1% gross margin. PMI currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with RVP at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RVP ACTIVE
Retractable Technologies Inc.
E 31/100 — 0.1% -23.3% -1.96% $16.9M Benchmark Subject
MODD
Modular Medical Inc.
E 33/100 — — -35.0% 0.00% $16.3M /modd-vs-rvp →
PAVM
PAVmed Inc.
E 28/100 — -30.0% -35.0% -1.01% $15.6M /pavm-vs-rvp →
CTSO
Cytosorbents Corporation
E 22/100 — 71.5% -35.0% +3.18% $14.3M /ctso-vs-rvp →
PMI
Picard Medical Inc.
D 48/100 — — — +2.96% $20.5M /pmi-vs-rvp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000946563 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Retractable Technologies Inc. (RVP) reported GAAP revenue of $38.3M (+15.8% vs. FY2024 revenue of $33.0M , and -12.2% cumulative change since FY2023) , GAAP net income of -$12.6M, operating cash flow of -$7.1M, and free cash flow of -$7.1M (+45.6% YoY). On the balance sheet, RVP closed FY2025 with $142.6M in total assets against $0 in total debt (Altman Z-Score: 0.52, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $38.3M -$12.6M -$7.1M -$7.1M $142.6M —
FY2024 (FY) 2024-12-31 $33.0M -$11.9M -$11.6M -$13.0M $160.7M $900.0K
FY2023 (FY) 2023-12-31 $43.6M -$7.0M $2.8M $2.8M — —

3. RVP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RVP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Retractable Technologies Inc. (NYSE: RVP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.56 (-1.96% 1D, market cap $16.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RVP ranks #772 in composite RQD confidence.

How does RVP compare to MODD and PAVM in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), RVP carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 0.1%, and ROIC of -23.3%. By comparison, MODD (Modular Medical Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and PAVM (PAVmed Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $15.6M). Among the 5-stock peer group, RVP leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RVP?

Per RVP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000946563), Retractable Technologies Inc. generated $38.3M in revenue (+15.8% YoY), -$12.6M in net income, and -$7.1M in free cash flow against $142.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RVP trading relative to its 50-day, 200-day, and 52-week technical levels?

RVP last traded at $0.56 (-1.96% on volume of 33,280 shares), positioning the stock -15.15% below its 50-day simple moving average ($0.66) and -17.65% below its 200-day simple moving average ($0.68). Across its 52-week range of $0.56 to $0.90, RVP sits at the 0.0% percentile with a 14-day RSI of 25.0 (OVERSOLD (<32)) and an implied next-earnings move of ±5.3% ($1.00 to $0.59).

Direct Sub-Reports: RVP RQD Cockpit RVP 12M Forecast RVP Earnings & Move RVP Dividends & DRIP RVP Insiders & 13F RVP Whale Options RVP Profit Sankey RVP News & Why
ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

RVP — Retractable Technologies Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Retractable Technologies Inc. (RVP) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.56 (-1.96% 1D, market capitalization $16.9M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -23.3%, gross margin of 0.1%, operating margin of -55.3%, and free cash flow yield of —.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.52, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Retractable Technologies Inc. Is classified in the Health Care sector and the Medical/Dental Instruments industry, and is listed on the NYSE.. — describes its specific products, customers, or revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Retractable Technologies Inc. (RVP) reported $38.3M in annual revenue (up from $33.0M in FY2024, +15.8% YoY) and -$12.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($43.6M revenue, -$7.0M net income) through FY2025, RVP scaled operating cash flow to -$7.1M and free cash flow to -$7.1M, backed by $142.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 11/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $0.56 – $0.90 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -55.3% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), RVP carries a macro regime beta of 1.00 and gross margin of 0.1%.

  • Key Question #1: Can RVP sustain or expand its -55.3% operating margin and -23.3% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $38.3M and free cash flow of -$7.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is RVP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RVP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Retractable Technologies Inc. (RVP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RVP Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RVP Bull vs. Bear Conversation Board — What's Your Call at $0.56?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RVP 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RVP:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $0.67 (+19.6%)
📌 Pinned Debate

Institutional accumulation and options positioning score 11/20 in the RQD rating, the strongest pillar relative to weight.

Long RVP at $0.56 targeting $0.67. Institutional accumulation and options positioning score 11/20 in the RQD rating, the strongest pillar relative to weight.. Institutional whale score is 11/20 and the risk/reward vs. the $0.56 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

Both sides have a point here — RVP's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $0.48 (-14.3%)
Spot @ $0.56

A 0.52 Altman Z-Score, 3/9 Piotroski F-Score, and -23.3% ROIC point to forensic balance sheet and cash-generation risk.

Here is the bear case nobody on the bull side wants to address on RVP: A 0.52 Altman Z-Score, 3/9 Piotroski F-Score, and -23.3% ROIC point to forensic balance sheet and cash-generation risk.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%